The surprise here was not the result of HA-I. It came in at 5.5 months and that was in line with the phase II results. The surprise was in the control arm which improved from every other trial including the phase II trail where it achieved 2.4 months. The in depth analysis should focus on why the control arm showed a statistically significant difference in this trial to every other trial.
Rev
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable